[1]慢性阻塞性肺疾病诊治指南 (2013年修订版) [J].中国医学前沿杂志 (电子版) , 2014, 6 (2) :67-80.
|
[2]
|
[2]SHUJAAT A, BAJWA A A, CURY J D.Pulmonary Hypertension Secondary to COPD[J].Pulmonary Medicine, 2012, 2012:203952.
|
[3]
|
[3]GALIE N, HOEPER M M, HUMBERT M, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension[J].Eur Heart J, 2009, 30:2493-2573.
|
[4]
|
[4]HILLAS G, PERLIKOS F, TSILIGIANNI I, TZANAKIS N.Managing comorbidities in COPD[J].International Journal of Chronic Obstructive Pulmonary Disease, 2015, 10:95-109.
|
[5]
|
[5]MARUNA P, NEDELNIKOVA K, GURLICH R.Physiology and genetics of procalcitonin[J].Physiological Research, 2000, 49:S57-S62.
|
[6]李珍, 徐鸥.降钙素原在慢性阻塞性肺疾病急性加重期的应用及进展[J].临床肺科杂志, 2015, 20 (4) :728-732.
|
[7]洪燕, 胡志雄, 周海英.降钙素原在慢性阻塞性肺病并肺动脉高压中的临床意义[J].中国医学工程, 2011, 19 (5) :26-28.
|
[8]林沛茹, 赵子文, 何桦, 李晓岩.Hs-CRP、降钙素原和动脉血气分析在慢性阻塞性肺疾病急性加重期合并肺动脉高压中的临床意义[J].实用医学杂志, 2016, 32 (2) :196-199.
|
[9]张晓慧, 李光韬, 张卓莉.C反应蛋白与超敏C反应蛋白的检测及其临床意义[J].中华临床免疫和变态反应杂志, 2011, 1 (1) :74-79.
|
[10]曹敬银, 陆元培.C反应蛋白在呼吸系统疾病中的研究进展[J].临床肺科杂志, 2010, 15 (9) :1290-1291.
|
[11]
|
[11]BLACK S, KUSHNER I, SAMOLS D, et al.C-reactive Protein[J].J Biol Chem, 2004, 279 (41) :48487-48490.
|
[12]
|
[12]KWONY S, CHI S Y, SHIN H J, et al.Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension.[J].Journal of Korean Medical Science, 2010, 25 (10) :1487-91.
|
[13]
|
[13]KISHIMOTO T.Interleukin-6:discovery of a pleiotropic cytokine.Arthritis Res Ther 2006, 8 (Suppl 2) :S2.
|
[14]王海龙, 孙丽蓉.IL-6基因多态性与COPD肺动脉高压研究进展[J].临床肺科杂志, 2011, 16 (12) :1928-1930.
|
[15]
|
[15]SAVALE L, TU L, RIDEAU D, et al.Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice[J].Respiratory Research, 2009, 10 (2) :1-13.
|
[16]
|
[16]CHAOUAT A, SAVALE L, CHOUAID CH, et al.Role for Interleukin-6 in COPD-Related Pulmonary Hypertension[J].Chest, 2009, 136 (3) :678-687.
|
[17]
|
[17]JOPPA P, PETRASOVA D, STANCAK B, et al.Systemic inflammation in patients with COPD and pulmonary hypertension[J].Chest, 2006, 130 (2) :326-333.
|
[18]陈刘通, 廖晨, 涂洪波, 等.吸烟及全身炎症反应与慢性阻塞性肺疾病患者中发生肺动脉高压的相关性研究[J].第三军医大学学报, 2016, (11) :1293-1296.
|
[19]
|
[19]WANG F, PAN W, PAN S, et al.Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients:a prospective, observational study[J].Critical Care, 2011, 15 (1) :1-9.
|
[20]
|
[20]CHI S Y, KIM E Y, BAN H J, et al.Plasma N-terminal Pro-brain Natriuretic Peptide:A Prognostic Marker in Patients with Chronic Obstructive Pulmonary Disease[J].Lung, 2012, 190 (3) :271-276.
|
[21]顾翔, 陈玉玲, 左丽娜, 等.hs-CRP、Fib、NT-pro BNP在COPD合并肺动脉高压中的研究及意义[J].临床肺科杂志, 2014, 19 (11) :1969-1972.
|
[22]
|
[22]BARBER J A.Mechanisms of development of chronic obstructive pulmonary disease-associated pulmonary hypertension[J].Pulm Circ, 2013, 3 (1) :160-4.
|
[23]
|
[23]ZHOU S, LI M, ZENG D, et al.Effects of basic fibroblast growth factor and cyclin D1 on cigarette smoke-induced pulmonary vascular remodeling in rats.[J].Experimental&Therapeutic Medicine, 2015, 9 (1) :33-38.
|